Abstracts tagged "combination therapies"

Abstract Number: 1348 • 2013 ACR/ARHP Annual Meeting
Initial Combination Therapy In Early Rheumatoid Arthritis: Which Patients Benefit?
I.M. Markusse¹, K.H. Han², A.J. Peeters³, H.K Ronday⁴, P.J.S.M. Kerstens⁵, T.W.J. Huizinga¹, W.F. Lems⁶ and C.F. Allaart¹, ¹Rheumatology, Leiden University Medical Center, Leiden, Netherlands, ²Rheumatology, Maasstad Hospital, Rotterdam, Netherlands, ³Rheumatology, Reinier de Graaf Gasthuis, Delft, Netherlands, ⁴Rheumatology, Haga Hospital, The Hague, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ⁶Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: Initial combination therapy has proven to be effective in early rheumatoid arthritis (RA) patients. To determine which patients benefit from initial combination therapy. Methods:…
Abstract Number: 1334 • 2013 ACR/ARHP Annual Meeting
Predicted Versus Observed Radiographic Progression In a Rheumatoid Arthritis Randomized Trial
Adrian Levitsky¹, Kristina Forslind^2,3 and Ronald F. van Vollenhoven⁴, ¹Department of Medicine, Unit for Clinical Therapy Research, Inflammatory Diseases (ClinTRID), The Karolinska Institute, Stockholm, Sweden, ²Department of Clinical Sciences, Section of Rheumatology, Skåne University Hospital, Lund, Sweden, ³Department of Medicine, Karolinska Institute, Stockholm, Department of Medicine, Karolinska Institute,, Stockholm, Sweden, ⁴Karolinska Institute, Stockholm, Sweden
Background/Purpose: Radiographic progression is a key outcome in early RA. We previously developed a radiographic progression prediction method based on the patient’s report of symptom…
Abstract Number: 282 • 2013 ACR/ARHP Annual Meeting
Rates Of Flare-Free Survival In Juvenile Idiopathic Arthritis When Tapering Individual Components Of Tumor Necrosis Factor Inhibitor and Methotrexate Combination Therapy
Caroline Y Chang¹, Rika Meyer² and Andreas Reiff¹, ¹Division of Rheumatology, Children's Hospital Los Angeles, Los Angeles, CA, ²Children's Hospital Los Angeles, Los Angeles, CA
Background/Purpose: Combination therapy of tumor necrosis factor inhibitors (TNFi) and methotrexate (MTX) is a well-established treatment that has dramatically changed outcomes in Juvenile Idiopathic Arthritis…
Abstract Number: L3 • 2013 ACR/ARHP Annual Meeting
A Phase 2b, 12-Week Study of VX-509, an Oral Selective Janus Kinase 3 Inhibitor, in Combination with Background Methotrexate in Rheumatoid Arthritis
MC Genovese¹, Ronald van Vollenhoven², Bradley J. Bloom³, John G. Jiang³ and Nils Kinnman⁴, ¹Stanford University, Palo Alto, CA, ²Karolinska Institute, Stockholm, Sweden, ³Vertex Pharmaceuticals Incorporated, Cambridge, MA, ⁴Vertex Pharmaceuticals Incorporated, Eysins, Switzerland
Background/Purpose: VX-509 is an oral selective JAK3 inhibitor being evaluated for the treatment of rheumatoid arthritis (RA). The objective of this 24-week, randomized, placebo-controlled, double-blind,…
Abstract Number: 2324 • 2013 ACR/ARHP Annual Meeting
Persistence On Biologics Is Associated With Concomitant Methotrexate Use Among Rheumatoid Arthritis Patient
Jie Zhang¹, Fenglong Xie², Elizabeth S. Delzell³, Huifeng Yun³, James Lewis⁴, Kevin Haynes⁵, Lang Chen⁶ and Jeffrey R. Curtis⁷, ¹Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ²Rheumatology & Immunology, University of Alabama at Birmingham, Birmingham, AL, ³Epidemiology, University of Alabama at Birmingham, Birmingham, AL, ⁴Medicine, University of Pennsylvania, Philadelphia, PA, ⁵Clinical Epidemiology and Biostatistics, University of Pennsylvania., Philadelphia, PA, ⁶Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, AL, ⁷University of Alabama at Birmingham, Birmingham, AL
Persistence on Biologics is Associated with Concomitant Methotrexate Use among Rheumatoid Arthritis Patient Background/Purpose: Concomitant methotrexate (MTX) is associated with improved treatment efficacy in randomized controlled…
Abstract Number: 2283 • 2013 ACR/ARHP Annual Meeting
The Evolving Use Of Biologic Monotherapy In Rheumatoid Arthritis and Its Impact On Patient Outcomes
Laurent Chanroux, Katrina Johnson and Joan Casellas, Therapy Watch, The Research Partnership, London, United Kingdom
Background/Purpose: The aim of our study is to understand whether the use of biologic monotherapy among rheumatoid arthritis (RA) patients is increasing and whether this…
Abstract Number: 1464 • 2013 ACR/ARHP Annual Meeting
Clinical and Radiographic Outcomes With Etanercept and Etanercept and Methotrexate In Patients With Rheumatoid Arthritis: Two-Year Results From The Canadian Methotrexate and Etanercept Outcome Study (CAMEO)
Boulos Haraoui¹, J. Carter Thorne², Edward C. Keystone³, Melanie Poulin-Costello⁴, Eric Trottier⁵, Andrew Vieira⁶ and Janet E. Pope⁷, ¹Department of Medicine, Centre Hospitalier de l’Université de Montréal, Montréal, QC, Canada, ²Southlake Regional Health Centre, Newmarket, ON, Canada, ³Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ⁴Biostatistics, Amgen Canada Inc., Mississauga, ON, Canada, ⁵Medical Communications, Amgen Canada, Mississauga, ON, Canada, ⁶Amgen Canada Inc., Mississauga, ON, Canada, ⁷St Joseph Health Care, London, ON, Canada
Background/Purpose: Data from the CAMEO study demonstrated that patients with rheumatoid arthritis (RA) who achieved low disease activity (LDA) after 6 months of combination therapy…
Abstract Number: 1424 • 2013 ACR/ARHP Annual Meeting
Persistence On Single Disease Modifying Anti-Rheumatic Drug Therapy In US Veterans With Rheumatoid Arthritis Is Extremely Rare
Jonathan Kruger¹, Ted R. Mikuls² and Grant W. Cannon³, ¹Salt Lake City VA and University of Utah, Salt Lake City, UT, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³Division of Rheumatology, Salt Lake City VA and University of Utah, Salt Lake City, UT
Background/Purpose: A limited number of rheumatoid arthritis (RA) patients are managed with a single disease-modifying anti-rheumatic drug (DMARD). Previous studies have suggested that DMARD naïve…
Abstract Number: 2488 • 2012 ACR/ARHP Annual Meeting
Magnetic Resonance Imaging Substudy in a Phase 2b Dose-Ranging Study of Baricitinib, an Oral Janus Kinase 1/Janus Kinase 2 Inhibitor, in Combination with Traditional Disease-Modifying Antirheumatic Drugs in Patients with Rheumatoid Arthritis
Charles G. Peterfy¹, Paul Emery², Mark C. Genovese³, Edward Keystone⁴, Peter Taylor⁵, Pierre-Yves Berclaz⁶, Julie C. DiCarlo¹, Chin H. Lee⁶, Douglas E. Schlichting⁶, Scott D. Beattie⁶, Monica E. Luchi⁷ and William Macias⁶, ¹Spire Sciences LLC, Kentfield, CA, ²Division of Rheumatic and Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ³Division of Rheumatology, Stanford University, Palo Alto, CA, ⁴University of Toronto, Toronto, ON, Canada, ⁵NDORMS, Botnar Research Centre, University of Oxford, Oxford, United Kingdom, ⁶Eli Lilly and Company, Indianapolis, IN, ⁷E361/309, Incyte Corporation, Wilmington, DE
Background/Purpose: Baricitinib (formerly, LY3009104/ INCB028050 ) is a novel, oral inhibitor of JAK1 and JAK2 in the JAK-STAT pathway. Primary results of this phase 2b…
Abstract Number: 1287 • 2012 ACR/ARHP Annual Meeting
Rheumatoid Arthritis Comparison of Active Therapies in Methotrexate Suboptimal Responders: Validation of the Strategy of Conventional Disease Modifying Anti-Rheumatic Drugs Before Biologicals
James R. O'Dell¹, Ted R. Mikuls², Thomas Taylor³, Vandana Ahluwalia⁴, Mary Brophy⁵, Stuart Warren⁶, Robert Lew⁵, Ciaran Phibbs⁷, Aslam H. Anis⁸, Amy C. Cannella⁹, Gary A. Kunkel¹⁰, Alan R. Erickson², Edward Keystone¹¹ and the CSP551 RACAT Research Group¹², ¹Dept of Internal Medicine, Omaha VA and University of Nebraska Medical Center, Omaha, NE, ²Omaha VA Medical Center and University of Nebraska Medical Center, Omaha, NE, ³VA Medical Center, White River Junction, VT, ⁴William Osler Health Center, Brampton, ON, Canada, ⁵VA Boston Heathcare System, Boston, MA, ⁶VA CSP Clinical Research Pharmacy Coordinating Center, Albuquerque, NM, ⁷Health Economics Resource Center (152), Palo Alto VA Health Care System, Menlo Park, CA, ⁸Population and Public Health, Univ of British Columbia, Vancouver, BC, Canada, ⁹Divison of Rheumatology, Omaha VA and University of Nebraska Medical Center, Omaha, NE, ¹⁰Div of Rheumatology, George Wahlen Veterans Affairs Medical Center, Salt Lake City, UT, ¹¹University of Toronto, Toronto, ON, Canada, ¹²Boston, MA
Background/Purpose: Double-blind placebo controlled randomized trials have demonstrated the efficacy of 15 different therapies in RA patients with active disease despite methotrexate (MTX). No blinded…
Abstract Number: 453 • 2012 ACR/ARHP Annual Meeting
Fish Oil in Rheumatoid Arthritis: A Randomised, Double Blind Trial Comparing High Dose with Low Dose
Susanna Proudman¹, Llew Spargo¹, Cindy Hall¹, Leah McWilliams¹, Anita Lee¹, Maureen Rischmueller², Robert Gibson³, Michael James¹ and Leslie G. Cleland¹, ¹Rheumatology Unit, Royal Adelaide Hospital, Adelaide, Australia, ²Rheumatology Department, Queen Elizabeth Hospital, Adelaide, Australia, ³University of Adelaide, Adelaide, Australia
Background/Purpose: The symptomatic benefit and NSAID-sparing effects of fish oil (FO) in RA are well known but effects on disease outcomes are less well established,…
Abstract Number: 353 • 2012 ACR/ARHP Annual Meeting
The Effect of Combination Therapy and Prednisolone On Haemostatic Markers in Rheumatoid Arthritis
Inge A.M. van den Oever¹, Danka J.F. Stuijver², Debby den Uyl³, Bregje van Zaane⁴, Marieke M. ter Wee⁵, Willem F. Lems⁵, Dirkjan van Schaardenburg¹, Joost C.M. Meijers⁴, Victor E.A. Gerdes⁴ and M. T. Nurmohamed⁶, ¹Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands, ²Vascular Medicine, Academic Medical Center, Amsterdam, Netherlands, ³Rheumatology, VU University medical centre, Amsterdam, Netherlands, ⁴Internal Medicine, Slotervaart Hospital, Amsterdam, Netherlands, ⁵Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁶VU University Medical Center/Jan van Bremen Research Institute, Amsterdam, Netherlands
Background/Purpose: There is accumulating evidence that rheumatoid arthritis (RA) should be considered as prothrombotic state, explaining the increased risk of thromboembolic events. Suppressing inflammation could…
Abstract Number: 354 • 2012 ACR/ARHP Annual Meeting
Delayed Onset of Hepatitis and/or Neutropenia in Patients with Rheumatoid Arthritis Treated with Combination Therapy of Methotrexate and Leflunomide
Seung Won Choi¹, Ji Seon Oh¹, You Jae Kim², Bon San Koo², Min Wook So², Yong-Gil Kim², Chang-Keun Lee² and Bin Yoo², ¹Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Ulsan University Hospital, Ulsan, South Korea, ²Division of Rheumatology, Department of Internal Medicine, University of Ulsan College of Medicine, Asan Medical Center, Seoul, South Korea
Background/Purpose: The adverse effects of combination therapy of methotrexate (MTX) and leflunomide (LEF) have been reported in many studies. Because combination of various doses of…
Abstract Number: 358 • 2012 ACR/ARHP Annual Meeting
Six Months of an Attenuated Cobra Regimen (‘COBRA-light’) Is Clinically Noninferior to the Original Cobra Regimen: An Open-Label Randomized Trial in Early Rheumatoid Arthritis
Debby den Uyl¹, Marieke M. ter Wee¹, Maarten Boers², Alexandre Voskuyl³, P.J.S.M. Kerstens⁴, Mike T. Nurmohamed⁵, Hennie G. Raterman¹, Dirkjan van Schaardenburg⁵, N. van Dillen⁴, B.a.C Dijkmans¹ and W.F. Lems¹, ¹Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ²Epidemiology & Biostatistics, VU University Medical Center, Amsterdam, Netherlands, ³Department of Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁴Rheumatology, Reade | Jan van Breemen Research Institute, Amsterdam, Netherlands, ⁵Rheumatology, Jan van Breemen Research Institute | Reade, Amsterdam, Netherlands
Background/Purpose: Early, intensive treatment of rheumatoid arthritis (RA) with combination therapy (COBRA therapy) considerably lowers disease activity and suppresses radiological progression. Although proven to be…
Abstract Number: 342 • 2012 ACR/ARHP Annual Meeting
Novel Combination Therapy of Existing Repurposed Therapies, Designed by Predictive Software Modeling, Shows Profound Impact On Disease Progression in a Murine Collagen-Induced Arthritis Model
Shireen Vali¹, Canio Refino², Jay Dela Cruz², Robinson Vidva¹, Prashant Nair¹, Saumya Radhakrishnan¹, Pradeep Fernandes¹, Taher Abbasi¹ and Gurkirpal Singh³, ¹CellWorks Group, Saratoga, CA, ²InTouch Bio, Alameda, CA, ³Gastroenterology/Hepatology, Stanford University School of Medicine, Palo Alto, CA
Background/Purpose: Rheumatoid Arthritis (RA) involves a complex interaction of multiple cell systems, cytokines and mediators. We recently developed a predictive software-based mathematical model that emulates…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].